Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings.

ABSTRACT: We performed a win ratio (WR) analysis of REPRIEVE, a randomized trial of pitavastatin vs placebo for cardiovascular disease in people with human immunodeficiency virus to assess robustness to event severity. WR aligns with primary findings and provides insight into pitavastatin protections: persistent advantage on death, stroke, and myocardial infarction. Clinical Trials Registration . NCT02344290.

SUBMITTER: Davies Smith E 

PROVIDER: S-EPMC12477884 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature